190 related articles for article (PubMed ID: 11740820)
1. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials.
Falardeau P; Champagne P; Poyet P; Hariton C; Dupont E
Semin Oncol; 2001 Dec; 28(6):620-5. PubMed ID: 11740820
[TBL] [Abstract][Full Text] [Related]
2. Neovastat--a novel antiangiogenic drug for cancer therapy.
Gingras D; Boivin D; Deckers C; Gendron S; Barthomeuf C; Béliveau R
Anticancer Drugs; 2003 Feb; 14(2):91-6. PubMed ID: 12569294
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue.
Dupont E; Falardeau P; Mousa SA; Dimitriadou V; Pepin MC; Wang T; Alaoui-Jamali MA
Clin Exp Metastasis; 2002; 19(2):145-53. PubMed ID: 11964078
[TBL] [Abstract][Full Text] [Related]
4. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.
Béliveau R; Gingras D; Kruger EA; Lamy S; Sirois P; Simard B; Sirois MG; Tranqui L; Baffert F; Beaulieu E; Dimitriadou V; Pépin MC; Courjal F; Ricard I; Poyet P; Falardeau P; Figg WD; Dupont E
Clin Cancer Res; 2002 Apr; 8(4):1242-50. PubMed ID: 11948139
[TBL] [Abstract][Full Text] [Related]
5. AE-941 (Neovastat): a novel multifunctional antiangiogenic compound.
Gingras D; Batist G; Béliveau R
Expert Rev Anticancer Ther; 2001 Oct; 1(3):341-7. PubMed ID: 12113101
[TBL] [Abstract][Full Text] [Related]
6. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels.
Batist G; Patenaude F; Champagne P; Croteau D; Levinton C; Hariton C; Escudier B; Dupont E
Ann Oncol; 2002 Aug; 13(8):1259-63. PubMed ID: 12181250
[TBL] [Abstract][Full Text] [Related]
7. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model.
Weber MH; Lee J; Orr FW
Int J Oncol; 2002 Feb; 20(2):299-303. PubMed ID: 11788892
[TBL] [Abstract][Full Text] [Related]
8. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
9. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis.
Sauder DN; Dekoven J; Champagne P; Croteau D; Dupont E
J Am Acad Dermatol; 2002 Oct; 47(4):535-41. PubMed ID: 12271297
[TBL] [Abstract][Full Text] [Related]
10. AE 941.
Drugs R D; 2004; 5(2):83-9. PubMed ID: 15293867
[TBL] [Abstract][Full Text] [Related]
11. AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma.
Bukowski RM
Expert Opin Investig Drugs; 2003 Aug; 12(8):1403-11. PubMed ID: 12882625
[TBL] [Abstract][Full Text] [Related]
12. Shark cartilage extracts as antiangiogenic agents: smart drinks or bitter pills?
Gingras D; Renaud A; Mousseau N; Béliveau R
Cancer Metastasis Rev; 2000; 19(1-2):83-6. PubMed ID: 11191068
[TBL] [Abstract][Full Text] [Related]
13. Neovastat (AE-941) inhibits the airway inflammation and hyperresponsiveness in a murine model of asthma.
Lee SY; Paik SY; Chung SM
J Microbiol; 2005 Feb; 43(1):11-6. PubMed ID: 15765051
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis inhibitors in the treatment of lung cancer.
Shepherd FA
Lung Cancer; 2001 Dec; 34 Suppl 3():S81-9. PubMed ID: 11740999
[TBL] [Abstract][Full Text] [Related]
15. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
16. AEterna reports on its phase II trial of neovastat.
Expert Rev Anticancer Ther; 2001 Jun; 1(1):3-4. PubMed ID: 12113128
[No Abstract] [Full Text] [Related]
17. The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity.
Gingras D; Labelle D; Nyalendo C; Boivin D; Demeule M; Barthomeuf C; Béliveau R
Invest New Drugs; 2004 Jan; 22(1):17-26. PubMed ID: 14707491
[TBL] [Abstract][Full Text] [Related]
18. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.
Aftab BT; Dobromilskaya I; Liu JO; Rudin CM
Cancer Res; 2011 Nov; 71(21):6764-72. PubMed ID: 21896639
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
20. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
